Report cover image

Global Assisted Reproduction Drug Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20361418

Description

Summary

According to APO Research, The global Assisted Reproduction Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Assisted Reproduction Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Assisted Reproduction Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Assisted Reproduction Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Assisted Reproduction Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Assisted Reproduction Drug include Ipsen Pharma Biotech, Zhejiang Xianju Pharmaceutical Co., Ltd., Solvay Pharma, Shanghai First Biochemical Pharmaceutical Co. LTD, Merck Sharp & Dohme, Merck Serono, Livzon Group and GenSci, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Assisted Reproduction Drug, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Assisted Reproduction Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Assisted Reproduction Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Assisted Reproduction Drug revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Assisted Reproduction Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Assisted Reproduction Drug revenue, projected growth trends, production technology, application and end-user industry.

Assisted Reproduction Drug Segment by Company

Ipsen Pharma Biotech
Zhejiang Xianju Pharmaceutical Co., Ltd.
Solvay Pharma
Shanghai First Biochemical Pharmaceutical Co. LTD
Merck Sharp & Dohme
Merck Serono
Livzon Group
GenSci
Assisted Reproduction Drug Segment by Type

Progestogen Hormone
Human Choroinic Gonadotrophin
Gonadotropin Releasing Hormone
Follicle-stimulating Hormone
Assisted Reproduction Drug Segment by Application

Controlled Ovarian Hyperstimulation
luteal Support
Down Regultion
Induced Ovulation
Assisted Reproduction Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproduction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproduction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproduction Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Assisted Reproduction Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Assisted Reproduction Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Assisted Reproduction Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Assisted Reproduction Drug Market by Type
1.2.1 Global Assisted Reproduction Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Progestogen Hormone
1.2.3 Human Choroinic Gonadotrophin
1.2.4 Gonadotropin Releasing Hormone
1.2.5 Follicle-stimulating Hormone
1.3 Assisted Reproduction Drug Market by Application
1.3.1 Global Assisted Reproduction Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Controlled Ovarian Hyperstimulation
1.3.3 luteal Support
1.3.4 Down Regultion
1.3.5 Induced Ovulation
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Assisted Reproduction Drug Market Dynamics
2.1 Assisted Reproduction Drug Industry Trends
2.2 Assisted Reproduction Drug Industry Drivers
2.3 Assisted Reproduction Drug Industry Opportunities and Challenges
2.4 Assisted Reproduction Drug Industry Restraints
3 Global Growth Perspective
3.1 Global Assisted Reproduction Drug Market Perspective (2020-2031)
3.2 Global Assisted Reproduction Drug Growth Trends by Region
3.2.1 Global Assisted Reproduction Drug Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Assisted Reproduction Drug Market Size by Region (2020-2025)
3.2.3 Global Assisted Reproduction Drug Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Assisted Reproduction Drug Revenue by Players
4.1.1 Global Assisted Reproduction Drug Revenue by Players (2020-2025)
4.1.2 Global Assisted Reproduction Drug Revenue Market Share by Players (2020-2025)
4.1.3 Global Assisted Reproduction Drug Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Assisted Reproduction Drug Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Assisted Reproduction Drug Key Players Headquarters & Area Served
4.4 Global Assisted Reproduction Drug Players, Product Type & Application
4.5 Global Assisted Reproduction Drug Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Assisted Reproduction Drug Market CR5 and HHI
4.6.3 2024 Assisted Reproduction Drug Tier 1, Tier 2, and Tier 3
5 Assisted Reproduction Drug Market Size by Type
5.1 Global Assisted Reproduction Drug Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Assisted Reproduction Drug Revenue by Type (2020-2031)
5.3 Global Assisted Reproduction Drug Revenue Market Share by Type (2020-2031)
6 Assisted Reproduction Drug Market Size by Application
6.1 Global Assisted Reproduction Drug Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Assisted Reproduction Drug Revenue by Application (2020-2031)
6.3 Global Assisted Reproduction Drug Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Ipsen Pharma Biotech
7.1.1 Ipsen Pharma Biotech Comapny Information
7.1.2 Ipsen Pharma Biotech Business Overview
7.1.3 Ipsen Pharma Biotech Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.1.4 Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio
7.1.5 Ipsen Pharma Biotech Recent Developments
7.2 Zhejiang Xianju Pharmaceutical Co., Ltd.
7.2.1 Zhejiang Xianju Pharmaceutical Co., Ltd. Comapny Information
7.2.2 Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview
7.2.3 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.2.4 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio
7.2.5 Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Developments
7.3 Solvay Pharma
7.3.1 Solvay Pharma Comapny Information
7.3.2 Solvay Pharma Business Overview
7.3.3 Solvay Pharma Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.3.4 Solvay Pharma Assisted Reproduction Drug Product Portfolio
7.3.5 Solvay Pharma Recent Developments
7.4 Shanghai First Biochemical Pharmaceutical Co. LTD
7.4.1 Shanghai First Biochemical Pharmaceutical Co. LTD Comapny Information
7.4.2 Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview
7.4.3 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.4.4 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio
7.4.5 Shanghai First Biochemical Pharmaceutical Co. LTD Recent Developments
7.5 Merck Sharp & Dohme
7.5.1 Merck Sharp & Dohme Comapny Information
7.5.2 Merck Sharp & Dohme Business Overview
7.5.3 Merck Sharp & Dohme Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.5.4 Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio
7.5.5 Merck Sharp & Dohme Recent Developments
7.6 Merck Serono
7.6.1 Merck Serono Comapny Information
7.6.2 Merck Serono Business Overview
7.6.3 Merck Serono Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.6.4 Merck Serono Assisted Reproduction Drug Product Portfolio
7.6.5 Merck Serono Recent Developments
7.7 Livzon Group
7.7.1 Livzon Group Comapny Information
7.7.2 Livzon Group Business Overview
7.7.3 Livzon Group Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.7.4 Livzon Group Assisted Reproduction Drug Product Portfolio
7.7.5 Livzon Group Recent Developments
7.8 GenSci
7.8.1 GenSci Comapny Information
7.8.2 GenSci Business Overview
7.8.3 GenSci Assisted Reproduction Drug Revenue and Gross Margin (2020-2025)
7.8.4 GenSci Assisted Reproduction Drug Product Portfolio
7.8.5 GenSci Recent Developments
8 North America
8.1 North America Assisted Reproduction Drug Revenue (2020-2031)
8.2 North America Assisted Reproduction Drug Revenue by Type (2020-2031)
8.2.1 North America Assisted Reproduction Drug Revenue by Type (2020-2025)
8.2.2 North America Assisted Reproduction Drug Revenue by Type (2026-2031)
8.3 North America Assisted Reproduction Drug Revenue Share by Type (2020-2031)
8.4 North America Assisted Reproduction Drug Revenue by Application (2020-2031)
8.4.1 North America Assisted Reproduction Drug Revenue by Application (2020-2025)
8.4.2 North America Assisted Reproduction Drug Revenue by Application (2026-2031)
8.5 North America Assisted Reproduction Drug Revenue Share by Application (2020-2031)
8.6 North America Assisted Reproduction Drug Revenue by Country
8.6.1 North America Assisted Reproduction Drug Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Assisted Reproduction Drug Revenue by Country (2020-2025)
8.6.3 North America Assisted Reproduction Drug Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Assisted Reproduction Drug Revenue (2020-2031)
9.2 Europe Assisted Reproduction Drug Revenue by Type (2020-2031)
9.2.1 Europe Assisted Reproduction Drug Revenue by Type (2020-2025)
9.2.2 Europe Assisted Reproduction Drug Revenue by Type (2026-2031)
9.3 Europe Assisted Reproduction Drug Revenue Share by Type (2020-2031)
9.4 Europe Assisted Reproduction Drug Revenue by Application (2020-2031)
9.4.1 Europe Assisted Reproduction Drug Revenue by Application (2020-2025)
9.4.2 Europe Assisted Reproduction Drug Revenue by Application (2026-2031)
9.5 Europe Assisted Reproduction Drug Revenue Share by Application (2020-2031)
9.6 Europe Assisted Reproduction Drug Revenue by Country
9.6.1 Europe Assisted Reproduction Drug Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Assisted Reproduction Drug Revenue by Country (2020-2025)
9.6.3 Europe Assisted Reproduction Drug Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Assisted Reproduction Drug Revenue (2020-2031)
10.2 China Assisted Reproduction Drug Revenue by Type (2020-2031)
10.2.1 China Assisted Reproduction Drug Revenue by Type (2020-2025)
10.2.2 China Assisted Reproduction Drug Revenue by Type (2026-2031)
10.3 China Assisted Reproduction Drug Revenue Share by Type (2020-2031)
10.4 China Assisted Reproduction Drug Revenue by Application (2020-2031)
10.4.1 China Assisted Reproduction Drug Revenue by Application (2020-2025)
10.4.2 China Assisted Reproduction Drug Revenue by Application (2026-2031)
10.5 China Assisted Reproduction Drug Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Assisted Reproduction Drug Revenue (2020-2031)
11.2 Asia Assisted Reproduction Drug Revenue by Type (2020-2031)
11.2.1 Asia Assisted Reproduction Drug Revenue by Type (2020-2025)
11.2.2 Asia Assisted Reproduction Drug Revenue by Type (2026-2031)
11.3 Asia Assisted Reproduction Drug Revenue Share by Type (2020-2031)
11.4 Asia Assisted Reproduction Drug Revenue by Application (2020-2031)
11.4.1 Asia Assisted Reproduction Drug Revenue by Application (2020-2025)
11.4.2 Asia Assisted Reproduction Drug Revenue by Application (2026-2031)
11.5 Asia Assisted Reproduction Drug Revenue Share by Application (2020-2031)
11.6 Asia Assisted Reproduction Drug Revenue by Country
11.6.1 Asia Assisted Reproduction Drug Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Assisted Reproduction Drug Revenue by Country (2020-2025)
11.6.3 Asia Assisted Reproduction Drug Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Assisted Reproduction Drug Revenue (2020-2031)
12.2 SAMEA Assisted Reproduction Drug Revenue by Type (2020-2031)
12.2.1 SAMEA Assisted Reproduction Drug Revenue by Type (2020-2025)
12.2.2 SAMEA Assisted Reproduction Drug Revenue by Type (2026-2031)
12.3 SAMEA Assisted Reproduction Drug Revenue Share by Type (2020-2031)
12.4 SAMEA Assisted Reproduction Drug Revenue by Application (2020-2031)
12.4.1 SAMEA Assisted Reproduction Drug Revenue by Application (2020-2025)
12.4.2 SAMEA Assisted Reproduction Drug Revenue by Application (2026-2031)
12.5 SAMEA Assisted Reproduction Drug Revenue Share by Application (2020-2031)
12.6 SAMEA Assisted Reproduction Drug Revenue by Country
12.6.1 SAMEA Assisted Reproduction Drug Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Assisted Reproduction Drug Revenue by Country (2020-2025)
12.6.3 SAMEA Assisted Reproduction Drug Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.